lung cancer
Conditions
Interventions
Low Risk/ Risk-Free group:Chemotherapy
High Risk/Medium Risk/Risk Group:PEG-rhG-CSF+ Chemotherapy
Sponsors
National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed small-cell lung cancer; 2. Patients have no history of chemotherapy, radiotherapy, immunotherapy, targeted therapy or more than 6 months after the end of the above treatment; 3. No surgical was performed recently; 4. No hematological disease; 5. Baseline peripheral blood routine blood test within the normal range; 6. Willing to participate in the experiment and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients have infections which are difficult to control; 2. Pregnant or lactating women; 3. Women of reproductive age who do not accept contraception; 4. Allergy to biological products; 5. Received antibiotic treatment within 72 hours before chemotherapy; 6. Received hematopoietic stem cell transplantation or organ transplantation; 7. Long-term use of hormones or immunosuppressants for autoimmune diseases or other reasons; 8. Severe mental or neurological disorders affect the expression or observation of informed consent and/or adverse reactions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| peripheral blood T-cell receptor repertoire; | — |
Secondary
| Measure | Time frame |
|---|---|
| lymphocyte subpopulation; | — |
Countries
China
Contacts
Public ContactWang Jie
Outcome results
None listed